Corcept Therapeutics Incorporated (CORT)

Total asset turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	482,375	450,026	428,153	413,824	401,858	397,624	392,027	380,229	365,978	352,891	343,087	340,064	353,874	356,034	351,212	334,904	306,486	285,422	268,362	258,417
Total assets	US$ in thousands	621,517	594,022	524,625	617,848	583,430	533,255	496,364	468,123	423,756	585,399	568,480	552,398	571,731	534,125	497,823	445,494	412,312	367,022	328,679	320,212
Total asset turnover		0.78	0.76	0.82	0.67	0.69	0.75	0.79	0.81	0.86	0.60	0.60	0.62	0.62	0.67	0.71	0.75	0.74	0.78	0.82	0.81

December 31, 2023 calculation

Total asset turnover = Revenue (ttm) ÷ Total assets
= $482,375K ÷ $621,517K
= 0.78

Corcept Therapeutics Inc's total asset turnover has fluctuated over the past eight quarters. The ratio has ranged from a low of 0.67 in Q1 2023 to a high of 0.82 in Q2 2023. This indicates that the company generated $0.67 to $0.82 in revenue for every dollar of assets during these periods.

The average total asset turnover for the period is approximately 0.76, suggesting that, on average, Corcept Therapeutics Inc generates $0.76 in revenue for each dollar of total assets employed. This indicates a moderate efficiency in generating revenue from its asset base.

It is important to note that a higher total asset turnover ratio generally indicates better asset utilization efficiency, as the company is generating more revenue from its assets. On the other hand, a lower ratio may suggest inefficiency in utilizing assets to generate revenue. Therefore, Corcept Therapeutics Inc should continue monitoring and seeking opportunities to improve its total asset turnover to enhance profitability and financial performance.